Article

Effectiveness of XBB.1.5 Vaccines Against Omicron Subvariants

2024-07-03

Abstract excerpt

<h4>Background</h4> The updated Moderna, Pfizer-BioNTech, and Novavax COVID-19 vaccines containing the SARS-CoV-2 omicron XBB.1.5 strain have replaced their predecessors in the United States and in other countries since the fall of 2023. The clinical impact of these vaccines on currently circulating variants was unknown. <h4>Aims</h4> We aimed to assess the effectiveness of the updated XBB.1.5 vaccines against cur...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ebb01cff-f465-5d96-8b59-cdcb9b565741
DOI: 10.1101/2024.07.01.24309806

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of XBB.1.5 Vaccines Against Omicron SubvariantsDOI 10.1101/2024.07.01.24309806Read

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concernSemantic proximity Read

Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysisSemantic proximity Read

Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity — IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024Semantic proximity Read

Increased vaccine sensitivity of an emerging SARS-CoV-2 variantSemantic proximity Read

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron VariantSemantic proximity Read

XBB.1.5 mRNA COVID-19 Vaccination and Inpatient or Emergency Department Visits Among Adults Infected with SARS-CoV-2 JN.1 and XBB-Lineage VariantsSemantic proximity Read

Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages — United States, May 2023–September 2024Semantic proximity Read

Increased vaccine sensitivity of an emerging SARS-CoV-2 variantSemantic proximity Read

Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trialSemantic proximity Read

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineagesSemantic proximity Read

<strong>Efficacy of COVID-19 Vaccines Against the Omicron Variant of SARS-CoV-2</strong>Semantic proximity Read

Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: impact of variant replacement and waning protection during 10-month follow-upSemantic proximity Read